The Role of Leptin Receptors in NASH

Completed

Conditions studied: Nonalcoholic Steatohepatitis, Metabolic Syndrome

In brief

NAFLD is a spectrum of liver diseases associated with varying degrees of hepatic steatosis, inflammation, and in some cases, fibrosis. NAFLD is a common observation in all demographics, but the prevalence of NAFLD and nonalcoholic steatohepatitis (NASH) is especially high in the morbidly obese population. Leptin is a cytokine that is encoded by the ob gene and primarily secreted by adipose tissue. The production of serum leptin increases with progressive obesity. Because of this observation, there has been significant interest in potential role of leptin in NAFLD. Our hypothesis is that we will find increased hepatic leptin and leptin receptor expression as the degree of hepatic injury worsens in NAFLD.

Key facts

Study ID

NCT00583999

Run by

University of California, Davis

People needed

104

Starts

2006-01-01

Expected to finish

2009-06-01

Last updated by the study team

2017-05-30

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• All patients undergoing elective bariatric surgery, ages 18-65.

You may not qualify if…

• non-obese patients, ages less than 18 and over 65. Pregnant patients.

Where it is running

• UC Davis Medical Center — Sacramento, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.